{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Scruggs BA"],"funding":["NEI NIH HHS","Heed Ophthalmic Foundation","Research to Prevent Blindness","Foundation Fighting Blindness","U.S. Department of Health & Human Services | National Institutes of Health"],"pagination":["601-607"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8958181"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(10-11)"],"pubmed_abstract":["Retinal damage has been associated with increased injection pressure during subretinal gene therapy delivery in various animal models, yet there are no human clinical data regarding the pressures required to initiate and propagate subretinal blebs. This study characterized the intraoperative pressure levels for subretinal gene therapy delivery across eight retinal conditions. A total of 116 patients with retinal degenerative diseases have been treated with subretinal gene therapy at OHSU-Casey Eye Institute as of June 2020; seventy patients (60.3%) were treated using a pneumatic-assisted subretinal delivery system. All retinal blebs were performed using a 41-gauge injection cannula, and use of a balanced salt solution (BSS) \"pre-bleb\" prior to gene therapy delivery was performed at the dis"],"journal":["Gene therapy"],"pubmed_title":["Injection pressure levels for creating blebs during subretinal gene therapy."],"pmcid":["PMC8958181"],"funding_grant_id":["Unrestricted grant to the Casey Eye Institute Department of Ophthalmology","Heed Fellowship Award","K08 EY026650","K08EY026650","P30EY010572","CD-NMT-0714-0648","P30 EY010572"],"pubmed_authors":["Pennesi ME","Scruggs BA","Yang P","Vasconcelos HM","Kogachi K","Matioli da Palma M","Bailey ST","Lauer AK"],"additional_accession":[]},"is_claimable":false,"name":"Injection pressure levels for creating blebs during subretinal gene therapy.","description":"Retinal damage has been associated with increased injection pressure during subretinal gene therapy delivery in various animal models, yet there are no human clinical data regarding the pressures required to initiate and propagate subretinal blebs. This study characterized the intraoperative pressure levels for subretinal gene therapy delivery across eight retinal conditions. A total of 116 patients with retinal degenerative diseases have been treated with subretinal gene therapy at OHSU-Casey Eye Institute as of June 2020; seventy patients (60.3%) were treated using a pneumatic-assisted subretinal delivery system. All retinal blebs were performed using a 41-gauge injection cannula, and use of a balanced salt solution (BSS) \"pre-bleb\" prior to gene therapy delivery was performed at the dis","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-05T11:27:51.089Z","creation":"2025-04-05T11:27:51.089Z"},"accession":"S-EPMC8958181","cross_references":{"pubmed":["34580433"],"doi":["10.1038/s41434-021-00294-2"]}}